Alfarona lyophilisate d / prig.r-ra d / intran. Introduction. 50000ME, No. 1

Intranasally.

The contents of the vial are dissolved in 5 ml of water for injection. At the first signs of acute respiratory viral infections, influenza: adults - 3 drops in each nasal passage 5-6 times a day (single dose - 3 thousand IU, daily - 15-18 thousand IU), newborns and children under 1 year old - 1 drop 5 times a day (single dose - 1 thousand IU, daily dose - 5 thousand IU), children from 1 to 3 years old - 2 drops 3-4 times a day (single dose - 2 thousand IU, daily - 6-8 thousand IU), from 3 to 14 years - 2 drops 4-5 times a day (single dose - 2 thousand IU, daily - 8-10 thousand IU) for 5 days.

For the prevention of acute respiratory viral infections and influenza: upon contact with a patient and / or hypothermia - in accordance with the age dosage, 2 times a day for 5-7 days. If necessary, preventive courses are repeated.

With a single contact, one instillation is sufficient. With a seasonal increase in morbidity - in accordance with the age dosage, in the morning, after 1-2 days. After instillation, it is recommended to massage the wings of the nose with your fingers to evenly distribute the drug in the nasal cavity.

Lyophilisate for preparation of a solution for intranasal administration in the form of a powder or porous mass of white or light yellow color, hygroscopic; the prepared solution is transparent, colorless or light yellow, without sediment or impurities.

1 fl.

interferon alpha-2b human recombinant 50,000 IU

Excipients: polyglucin, sodium chloride, monosodium phosphate dihydrate, sodium phosphate disubstituted.

• Severe forms of allergic diseases,

• individual intolerance to interferon preparations.

Pharmacodynamics

Human recombinant interferon alpha-2b is a protein synthesized by the Escherichia coli strain, in the genetic apparatus of which the gene for human leukocyte interferon alpha-2b is inserted. Identical to human leukocyte interferon alpha-2b.

Pharmacokinetics

Lyophilisate for the preparation of a solution for injection and topical application: when administered parenterally, it degrades, partially excreted unchanged, mainly through the kidneys.

The drug, like all interferons, can lead to the appearance of antibodies to interferon and, as a result, to a decrease in the therapeutic effect.

Interaction

Lyophilisate for the preparation of a solution for intranasal administration: the simultaneous use of intranasal vasoconstrictor drugs is not recommended (contributes to additional drying of the nasal mucosa).